• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell res

tetano

Editor, Senior Moderator
Cell Rep


. 2022 Jan 19;110345.
doi: 10.1016/j.celrep.2022.110345. Online ahead of print.
Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses


Harikrishnan Balachandran[SUP] 1 [/SUP], Chansavath Phetsouphanh[SUP] 2 [/SUP], David Agapiou[SUP] 2 [/SUP], Anurag Adhikari[SUP] 3 [/SUP], Chaturaka Rodrigo[SUP] 1 [/SUP], Mohamed Hammoud[SUP] 2 [/SUP], Lok Bahadur Shrestha[SUP] 1 [/SUP], Elizabeth Keoshkerian[SUP] 2 [/SUP], Money Gupta[SUP] 1 [/SUP], Stuart Turville[SUP] 2 [/SUP], Daniel Christ[SUP] 4 [/SUP], Cecile King[SUP] 4 [/SUP], Sarah C Sasson[SUP] 2 [/SUP], Adam Bartlett[SUP] 5 [/SUP], Branka Grubor-Bauk[SUP] 6 [/SUP], William Rawlinson[SUP] 7 [/SUP], Anupriya Aggarwal[SUP] 2 [/SUP], Alberto Ospina Stella[SUP] 2 [/SUP], Vera Klemm[SUP] 2 [/SUP], Michael M Mina[SUP] 8 [/SUP], Jeffrey J Post[SUP] 9 [/SUP], Bernard Hudson[SUP] 10 [/SUP], Nicky Gilroy[SUP] 11 [/SUP], Pam Konecny[SUP] 12 [/SUP], Golo Ahlenstiel[SUP] 13 [/SUP], Dominic E Dwyer[SUP] 14 [/SUP], Tania C Sorrell[SUP] 15 [/SUP], Anthony Kelleher[SUP] 2 [/SUP], Nicodemus Tedla[SUP] 16 [/SUP], Andrew R Lloyd[SUP] 2 [/SUP], Marianne Martinello[SUP] 17 [/SUP], Rowena A Bull[SUP] 18 [/SUP], COSIN Study Group



Affiliations

Abstract

Understanding the long-term maintenance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity is critical for predicting protection against reinfection. In an age- and gender-matched cohort of 24 participants, the association of disease severity and early immune responses on the maintenance of humoral immunity 12 months post-infection is examined. All severely affected participants maintain a stable subset of SARS-CoV-2 receptor-binding domain (RBD)-specific memory B cells (MBCs) and good neutralizing antibody breadth against the majority of the variants of concern, including the Delta variant. Modeling these immune responses against vaccine efficacy data indicate a 45%-76% protection against symptomatic infection (variant dependent). Overall, these findings indicate durable humoral responses in most participants after infection, reasonable protection against reinfection, and implicate baseline antigen-specific CD4+ T cell responses as a predictor of maintenance of antibody neutralization breadth and RBD-specific MBC levels at 12 months post-infection.

Keywords: 12 months after SARS-CoV-2 infection; Delta variant; RBD-specific memory B cells longevity; SARS-CoV-2; SARS-CoV-2 OX40 CD4 T cell assay; SARS-CoV-2 antibody duration; SARS-CoV-2 neutralization; protection efficacy prediction; variants of concern.
 
Back
Top Bottom